Biomerica provides update on inFoods IBS expansion - Seite 2
The American College of Gastroenterology (ACG) reports that IBS impacts 1 in 20 Americans and that up to $10 Billion is spent each year in direct medical cost due to IBS. Yet, due to the complexity of the disorder, and the lack of effective therapies, IBS patients still struggle to find effective relief.
The inFoods IBS product has been studied in a prospective double blinded, placebo-controlled endpoint study at several prominent medical centers including Mayo Clinic, Beth Israel Deaconess Medical Center Inc. – a Harvard Medical School Teaching Hospital, Houston Methodist Hospital, and the University of Michigan. The study results demonstrated a significant improvement in Abdominal Pain Intensity (API) (trial participants with >30% reduction in pain) for IBS patients in the treatment diet arm compared to those in the placebo diet arm (p-value of 0.0246).
Biomerica remains at the forefront of innovative GI solutions, with the inFoods IBS product exemplifying its dedication to improving patient lives. The Company remains steadfast in its mission to enhance gastrointestinal care, reduce healthcare costs, and improve the quality of life of approximately 750 million individuals suffering from IBS around the world.
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets
advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical
conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focuses on gastrointestinal
and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
Lesen Sie auch
About inFoods
The inFoods IBS test is designed to assess a patient’s above normal immunoreactivity to specific foods utilizing a simple finger-stick blood sample. Instead of difficult to manage broad dietary
restrictions, physicians can now use the inFoods IBS information to make targeted, patient-specific recommendations about trigger foods that, when removed from the diet, may alleviate IBS symptoms
such as pain, bloating, diarrhea and constipation. The inFoods IBS test and clinical outcomes were studied at several prominent centers including Mayo Clinic, Beth Israel Deaconess Medical Center
Inc. - a Harvard Medical School Teaching Hospital, Houston Methodist Hospital, and the University of Michigan. The clinical results for improvement in the Abdominal Pain Intensity (API) responder
endpoint of >30% reduction in pain, for IBS patients in the treatment diet arm was greater than patients in the placebo diet arm (p-value of 0.0246). The improvement for patients in the
treatment arm versus the placebo arm is considered clinically significant and for certain endpoints is similar and, in some cases, better than the current drugs in the market. Further information
about Biomerica’s patented inFoods Technology Platform can be found at: https://biomerica.com/inFoods/our-technology/.